1006879-02-2

Basic information

• Product Name: 2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidine-4,5-diamine
• Synonyms: 2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidine-4,5-diamine
• CAS NO: 1006879-02-2
• Molecular Weight: 382.235
• Mol File: 1006879-02-2.mol

Chemical Properties

• CAS DataBase Reference: 2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidine-4,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidine-4,5-diamine(1006879-02-2)
• EPA Substance Registry System: 2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidine-4,5-diamine(1006879-02-2)

Safety Data

• Hazardous Substances Data: 1006879-02-2(Hazardous Substances Data)

Upstream product

• 14631-08-4 2-chloro-4,5-diaminopyrimidine 
• 916971-27-2 4-(2-bromo-5-fluorophenoxy)piperidine 

Downstream Products

• 1006879-01-1 5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-3H-[1,2,3]triazolo[4,5-d]-pyrimidine 
• 1006879-07-7 2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-9H-purine-8-thiol 
• 1108199-73-0 ethyl N-(2-{4-[(2-bromo-5-fluorophenyl)oxy]piperidin-1-yl}-9H-purin-8-yl)glycinate 
• 1108199-66-1 4-{4-amino-2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidin-5-amino}-4-oxobutanoic acid 

Relevant articles and documents

BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. Formula (I).